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Rapid assessment cross-sectional surveys and qualitative interviews were conducted among people who inject 
drugs (PWID) in Burundi and Uganda, as well as key informants working with drug users, to assess risk associated 
with HIV and hepatitis C (HCV). A total of 127 PWID were recruited in Burundi and 125 in Uganda of which the 
majority were male and aged between 24 and 26 years. Blood samples were collected in Burundi to test for 
antibodies to HIV, HCV and B Surface Antigen (HBsAg). Heroin was mainly injected in Uganda and Burundi 
with a small minority injecting crack/cocaine. Half of participants in Burundi, and 86% in Uganda had been HIV 
tested. The minority had been tested for HCV in any site (5-7%). HIV prevalence from the serological testing in 
Burundi indicated that 10% tested positive for antibodies to HIV, 6% to HCV and 9% to HBsAg. Qualitative data 
suggested that structural factors including costs of needle/syringes as well policies prohibiting pharmacies selling 
injecting equipment to PWID were related to reuse and sharing of needles/syringes among PWID, despite 
awareness HIV transmission risk. Police arrest was common in Burundi and Uganda and the use of bribes by 
police compounded existing high levels of poverty. Findings accentuate the need for policy shifts to enable easier 
access to clean injecting equipment, increased availability of HIV and HCV testing and  increased access to 
affordable drug treatment and introduction of opioid substitution therapy. Specific attention is needed to the 
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Introduction 
Injecting drug use is reported in 20 countries across Sub-Saharan Africa attributed to changes in trafficking routes 
and the introduction of heroin more suited to injecting than smoking.1 Sub-Saharan Africa has 12% of the world’s 
population but 71% of HIV infections, with HIV prevalence among adult populations estimated at 1.1% in 
Burundi and 6.5% in Uganda.2 Injecting drugs has been associated with concentrated outbreaks of HIV infection 
in both high and low-income settings.3 HIV prevalence among people who inject drugs (PWID) is estimated to be 
15% in Kenya, 20% in Tanzania and 45% in Uganda 2,4 5 Little is known regarding regional Hepatitis C (HCV) 
prevalence and risk among PWID. 
 
There is growing governmental commitment across the East African region for harm reduction interventions as a 
means to prevent HIV among PWID, including opioid substitution therapy (OST), needle syringe programs (NSP) 
and HIV testing and treatment.6 Yet the implementation of these interventions is nascent, with OST and NSP only 
available in Mauritius, Madagascar, Tanzania and Kenya.6 Concentrated HIV epidemics nested inside generalized 
and sexually-driven epidemics pose particular challenges for intervening. There is an urgent need for data on the 
extent of injecting drug use and associated HIV risk behavior to inform their development and scale up. We 
undertook rapid assessments in Burundi and Uganda in order to generate initial evidence on the extent of injecting 
drug use and HIV and HCV risks for use in mobilizing resources to support the development of harm reduction 
interventions to prevent and treat HIV and HCV infections among PWID. 
 
Methodology 
Rapid assessments combine qualitative with quantitative data generation methods to quickly inform intervention 
design, action and advocacy.7 We conducted cross-sectional surveys among PWID in Burundi (Bujumbura), 
Uganda (Kampala and Mbale). To be eligible, participants had to have injected in the last 3 months, be older than 
18 years (Uganda) or if younger legally recognized as being capable of assuming adult responsibilities (Burundi). 
 
Following informed consent, behavioral data on HIV risk practices and service use were generated via an 
interviewer-administered questionnaire. Whole blood samples were collected in Burundi at health centers, and 
tested following clinical screening procedures testing for anti-bodies to HIV, HCV and Hepatitis B Surface 
Antigen (HBsAg). Supplementary qualitative data generation comprised semi-structured interviews and focus 
group discussions (FGD) with PWID recruited from community settings and key informants working with PWID. 
Ethical approval was granted by the national ethical committee in Burundi, the Mildmay Research Ethics 




Cross sectional surveys and secondary data 
We recruited 127 PWID in Burundi and 125 in Uganda. The minority of participants were female: 7% in Burundi 
and 18% in Uganda. On average, PWID were slightly younger in Burundi compared to Uganda (median=24 and 
26 years) and with higher levels of homelessness (22% and 10%). Approximately half of the sample had ever 
exchanged sex for money, drugs or goods, among whom 63% and 81% used a condom at last sex work in Burundi 
and Uganda respectively. (Table 1) In Uganda all female and 26% of male participants had engaged in sex work 
while in Burundi 78% of women and 49% of men had done so (data not shown). 
 
The main drug injected in both countries was heroin, but between 6% and 10% injected crack/cocaine. The median 
duration of injecting was 4.5 years (Burundi) and 5 years (Uganda). In Burundi 21% injected daily and 15% in 
Uganda. In the last three months, approximately half the sample had injected with a used needle/syringe in both 
sites (49-58%). Shared use of any injecting equipment (filters, spoons, rinse water) was reported by 53% in 
Burundi and 75% in Uganda in the last three months, and in both countries, approximately 70% used the same 
needle/syringe for injecting twice or more over the same time period.  
 
Pharmacies were the main source for obtaining new needles/syringes (61% Burundi, 67% Uganda) then friends 
or drug dealers (27% Burundi, 24% Uganda,) with health facilities the least common (5% Burundi, 15% Uganda). 
A higher proportion had recent contact with a peer educator in Uganda (57%) compared to Burundi (34%). 
 
Half of participants in Burundi had ever been tested for HIV and 86% in Uganda, but only the minority had been 
tested for HCV (5-7%), testing for which is not routinely offered in either country. Lifetime uptake of treatment 
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to modify drug use was low in Uganda (15%) and Burundi (3%) and experience of overdosing was high: 40% 
(Burundi); and 53% (Uganda). Serological testing in Burundi indicated that 10% of the sample were positive for 
antibodies to HIV, 6% to HCV and 9% to HBsAg. There were few cases of HIV/HCV coinfection (1), 
HIV/HBsAg (2) and no cases of HCV/HBsAg coinfection or triple infection (data not shown). HIV prevalence 
was 22% among women and 9% among men.   
 
The majority of the sample had been arrested by the police in the last 12 months in Burundi (76%) and Uganda 
(65%). High proportions had experienced violence from the police in the same time frame (77% Burundi, 49% 
Uganda). Over half of participants in Burundi (55%) and Uganda (59%) had ever been in prison with 34% 
injecting with a used needle/syringe while in prison in Burundi and 15% in Uganda.  
 
Focus groups and key informant interviews  
In Burundi, nine interviews with key informants from the police, Ministry of Health, and local community were 
conducted as well as three FGD with PWID (n=8),  people with experience of injecting drug use (n=8) and health 
service providers (n=8). In Uganda a total of 30 key informants from health services, police and the Ministry of 
Health were interviewed. Twelve focus group discussions were conducted in Kampala and 5 in Mbale among 
PWID.  
 
Qualitative data indicated that cost and pharmacy restrictions selling needles/syringes to drug users was related to 
the sharing of injecting equipment “We are vulnerable! If I have 5000 Fbu [3 USD] to buy a single dose, I leave 
money for a needle, but you can’t even find one nearby…..I quickly go to a friend nearby to borrow his needle 
because by now my body is burning from lack of heroin. Now HIV or AIDS does not mean anything to you, you 
think about it later!” [PWID, Bujumbura, Burundi] Needle/syringe sharing continued despite awareness of HIV 
transmission risks.  
 
Barriers to accessing services in both Uganda and Burundi included stigma and discriminations, as well as a lack 
of harm reduction services for PWID and high costs of accessing private health services “even after we have 
overdose and blacked out, and we attempt to go to the health facilities, they delay to attend us, because they look 
at us as though we are useless. They think we are deviants and thugs, so they don’t hurry to give us treatment.” 
(FGD, Mbale) Existing problems related to poverty were compounded by the need to bribe police to avoid arrest 
as well as experiencing violence from police  “when we [PWID] use these drugs, they [the police] arrest us, saying 
we are destabilizing the community, […] and when they [the police] arrest you, they demand money in order to 
release you”. (FGD, Bujumbura Burundi)   
 
Discussion and recommendations 
We found a high prevalence of HIV and HBsAg but low prevalence of HCV among PWID in Burundi. Survey 
results suggested injecting with used, as well as reuse of, needles/syringe was common. Participants reported poor 
access to drug treatment and health facilities. Despite the presence of needle/syringe exchange programs in both 
countries, pharmacies, then friends were the main source for obtaining needles/syringes. There was a considerable 
overlap between experience of sex work and injecting drug use.  
 
Access to clean injecting is poor as evidenced by high levels of sharing and reuse of the same needles/syringe for 
injecting. We found that high cost as well as policies that prohibit pharmacies from selling needles/syringes to be 
a key barrier for PWID to obtaining injecting equipment as well as intensive policing practices and violence from 
police.  
 
Uptake of HIV testing is higher than previously documented in the region8, particularly in Burundi, although 
uptake of HCV testing is low in both countries and availability needs to be increased. In both sites 46% had 
engaged in sex work, with the majority of women reporting experience of sex work. Data from Burundi suggest 
a higher prevalence of HIV among women than men. A similar difference has been documented in Kenya and 
Tanzania.4 Harm reduction interventions need to address the additional vulnerabilities experienced by women 
who inject drugs, including risks of sexual transmission of HIV.  
 
Despite attempts to recruit a diverse sample of PWID in all sites through the use of community mapping, these 
rapid assessments are limited by the lack of probabilistic sampling methods and small sample. Findings therefore 
may not represent the broader population of PWID. Despite these limitations, the study provides important new 
evidence of injecting drug use, particularly in Burundi, where injecting has not been documented before 
suggestive of increased diffusion of injecting.3 There is a need for further in depth research, as well as the 
introduction of harm reduction interventions designed to facilitate low threshold access to services and the 
removal of restrictions on access to clean injecting equipment. 
  
Table 1: Characteristics of people who inject drugs in Burundi and Uganda.  
 Burundi  Uganda 
 % (n) or Median (IQR) 
Total  127 125 
Demographic characteristics   
Age (years) 24 (IQR 20-30) 26 (IQR 23-30) 
Female 7% (9 18% (23) 
Having no fixed abode  22% (28) 10% (12) 
History of drug use   
Drug injected   
Heroin  98% (117) & 87% (109)  
Cocaine/crack  10% (13) & 6% (7) 
Duration of injecting (years) 4.5 (2-9) 5 (3-8) 
Daily injecting  21% (27) 15% (19) 
Injecting risk behaviours (3 months)   
Injected with a used needle/syringe 49% (62) 58% (72) 
Sharing injecting equipment ^^ 53% (67)  75% (94) 
Used a needle twice or more  71% (85) 69% (83) 
Sexual risk behaviours   
Ever exchanged sex 51% (65) 40% (49) 
Used a condom at last sex work  63% (41) 81% (41) 
Access to services    
Main source of needles/syringes   
Pharmacy 67% (50) 61% (75) 
Health facility 5% (4) 15% (19) 
Friends/other drug users 27% (20) 24% (29) 
Contact with a peer educator (3 month) 34% (43) 57% (71) 
Ever tested for HIV 50% (64) 86% (107) 
Ever tested for HCV 5% (6) 7% (9) 
Ever received drug treatment 3% (4) 15% (19) 
Biological  indicators    
Anti-HIV 10% (13) 45% (243)* 
Anti-HCV 6% (7) 2% (9)* 
HBsAg infection 9% (12) 3 (13)* 
Health indicators   
Ever had an STI 22% (28) 57% (71) 
Ever overdosed 40% (51) 53% (66) 
Contact with criminal justice system   
Arrested in the last 12 months 76% (96) 65% (81) 
Experienced police violence  77% (98) 49% (61) 
Ever been in prison 55% (70) 59% (71) 
Injected with used n/s while last in prison 34% (24) 15% (11) 
& Main drug injected: Burundi, numbers do not add up as multiple responses were allowed and 21 people who smoked heroin; ^^ Sharing of injecting 
equipment was defined as shared use of filters or syringes in Burundi, and shared use of filters, spoons or frontloading in Uganda.  *Data collated 
from Ugandan Harm Reduction Network client records. Total number of cases for HIV testing is 511, 546 for HCV, and 445 for HBsAg.    
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